Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive deep brain stimulation, a technology that’s currently under review at the ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
The FDA approved Medtronic’s AdaptiveStim with the RestoreSensor neurostimulation system, according to a Medtronic news release. The system uses motion sensor technology to automatically adapt ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced ...
Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...
Fridley-based Medtronic, Inc., disclosed in a Wednesday regulatory filing that it has been subpoenaed for information relating to some of its neurostimulation devices. According to the U.S. Securities ...
Medtronic has launched a study of its neurostimulation therapy device to optimal medical management along for the treatment of failed back surgery syndrome and low back pain. The study is a ...
Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results